CUPR logo

CUPRINA HOLDINGS CAYMAN-A

CUPRNASDAQ
πŸ† #5079 by market capUS Equity
$2.01β–² $0.06 (+3.08%)
πŸŒ™ After hours$2.00β–Ό 0.49%Regular close Β· extended-hours price shown
πŸ””
Track CUPR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 3.1%
7dβ–² 1.0%
14dβ–Ό 35.4%
30dβ–Ό 28.5%
ytdβ–Ό 37.7%
1yβ–Ό 73.6%
🏦Market Cap
$5M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
-0.4%
Thin
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
171.8x
Expensive
Otter Score
80
Good

Trading Snapshot

Day Range
$1.99 – $2.05
52-Week Range
β€”
Volume
$2.61B
Avg Volume
$3.26B
Shares Outstanding
2.7M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$49,894
Last Q Revenue
$26,790
P/E Ratio
β€”
P/S Ratio
171.8x
EPS (TTM)
β€”
Dividend Yield
β€”

Why Investors Own CUPR

  • βœ“High-growth profile β€” revenue up +25.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 66% gross margin and 22% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CUPR logo

CUPRINA HOLDINGS CAYMAN-A

CUPR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$50Kβ–² +3.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-1.3%β–Ό βˆ’79.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$5Mβ–² +177.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$9Mβ–² +630.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About CUPRINA HOLDINGS CAYMAN-A

Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
80/100

Analyst Price Target

β“˜
Average Target
$2.09
β–² +4.2% Upside
High Target$2.48
Low Target$1.57
Based on 26 analysts

Latest News & Updates